Cefuroxime is a cephalosporin indicated for the treatment of a variety of infections including acute bacterial otitis media, several upper respiratory tract infections, skin infections, urinary tract infections, gonorrhea, early Lyme disease, and impetigo. Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase.
- Mechanism
- Curator reviewed
Cefuroxime, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefuroxime interferes with an autolysin inhibitor.
- Primary indication
- For the treatment of many different types of bacterial infections such as bronchitis, sinusitis, tonsillitis, ear infections, skin infections, gonorrhea, and urinary tract infections.Curator reviewed · 19 structured indications
- Formula / weight
- C16H16N4O8S · 424.385 g/mol (avg)
- First approval
- Canada, 2001 · United States, 1989
- Also known as
- Cefuroxim · Cephuroxime
- Brand names
Resolves to
JFPVXVDWJQMJEE-IZRZKJBUSA-NSMILES[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CC=CO1)C(O)=OWhat you can answer from here — as of September 19, 2026
Which drugs share a target with Cefuroxime, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account